EHA 2016 | Killer antibodies against AML
Press brief by Mette Hazenberg, MD, PhD of the Academic Medical Center, Amsterdam, Netherlands, at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up
An exciting era for CAR T-cell therapy
Harmonizing MRD reporting criteria
MRD testing will be a part of future AML clinical trials
Improving the specificity of molecular MRD detection
Targeted RNA-sequencing for the quantification of MRD in AML